Summit Therapeutics doses first patient in antibiotic trial

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 13:10

Summit Therapeutics said it had dosed the first patient in the third phase of a clinical trial of an antibiotic to treat C.difficile infection.

The treatment, ridinilazole, had achieved statistical superiority over the standard of care, vancomycin, in the phase-two clinical trial.

'With positive results, we believe ridinilazole could be positioned as the drug of choice in the front-line treatment of C.difficile infection, which potentially provides patients with sustained cures and hospitals with compelling cost savings,' chief executive Glyn Edwards said.

At 1:10pm: (LON:SUMM) Summit Therapeutics PLC share price was +0.5p at 23.5p

Related content

Summit Therapeutics CEO Glyn Edwards to present at San Francisco conference

Summit Therapeutics said chief executive Glyn Edwards would present at an industry conference in San Francisco.

Edwards would present at the 2019 BIO Investor Forum...

Wed, 16/10/2019 - 13:11

Summit Therapeutics losses deepen on higher R&D spend

Pharmaceutical company Summit Therapeutics posted a deeper second-quarter loss amid a rise in R&D spending.

Pre-tax losses for the three months through September amounted to...

Fri, 11/10/2019 - 13:52

Summit Therapeutics highlights potential of gonorrhoea treatment at key conference

Summit Therapeutics said that it had highlighted the potential of its pre-clinical new class antibiotic to treat all gonorrhoea, including multi-drug resistant strains, at the...

Wed, 17/07/2019 - 13:08

Summit Therapeutics books first-quarter loss on higher R&D spend

Antibiotics developer Summit Therapeutics booked a first-quarter loss as it ramped up R&D spending.

Pre-tax losses for the three months through March amounted to...

Wed, 12/06/2019 - 13:09

Summit Therapeutics presents antibiotic concept data at Amsterdman conference

Summit Therapeutics said it had presented proof of concept data for a series of new antibiotics at a conference in Amsterdam.

The data was presented...

Mon, 15/04/2019 - 08:06